10-14-13 5:00 AM EDT | Email Article

Findings from studies investigating clinical validity of non-invasive cancer-mutation monitoring platform will be shared for first time at AACR-NCI-EORTC conference on October 21, 2013

SAN DIEGO, Oct. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that two abstracts (#B175 and #B177) highlighting results from studies of the company's novel, non-invasive cancer mutation monitoring platform will be presented on October 21, 2013 at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Both studies were completed in collaboration with Dr. Filip Janku in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston. Trovagene is developing proprietary cell-free DNA urinary assays for molecular testing as a non-invasive alternative to mutation testing of tumor tissue.

The abstracts accepted for presentation during the "Molecular Classification of Tumors" poster session at the AACR-NCI-EORTC conference are:

Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by digital droplet PCR (Abstract #B175)

  • Monday, October 21, 12:30 – 3:00 p.m. and 6:30 – 7:30 p.m.
  • Location: Exhibit Hall C-D

Non-invasive tumor mutation detection of cell-free urinary DNA using massively parallel deep DNA sequencing (Abstract #B177)

  • Monday, October 21, 12:30 – 3:00 p.m. and 6:30 – 7:30 p.m.
  • Location: Exhibit Hall C-D

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

Contact:
Amy Caterina
Trovagene, Inc.
Investor Relations
858-952-7593
acaterina@trovagene.com

[1] American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer

SOURCE Trovagene, Inc.

Add a Comment

News   More...

OncoMed Pharmaceuticals to Present Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (anti-CSC) Therapeutics in Five Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013 (2013/10/14)
OncoMed Pharmaceuticals Presents Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013 (2013/10/21)
OncoMed Pharmaceuticals Updates Phase 1b Data for Demcizumab With Pemetrexed and Carboplatin in Patients With First-Line Stage IIIb/IV Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013 (2013/10/20)
Five Data Presentations on BioMarin's BMN 673 PARP Inhibitor at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2013/10/20)
Merrimack Pharmaceuticals to Present Preclinical Data at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2013/10/15)
Agenus to Present at the 4th Annual Cancer Immunotherapy Conference (2014/3/26)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2013 Credit Suisse Healthcare Conference (2013/11/6)
Watts Water Technologies Announces Webcast of Its Presentation at the 2013 RBC Capital Markets Conference ()
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 Leerink Global Healthcare Conference (2014/2/5)
Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting (2014/4/1)
Securities related to this article
TrovaGene, Inc. View trov Stock Quote
TrovaGene, Inc. View trov Stock Quote
 
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - 2013/10/14 - Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: Trovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer  |  Next: Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting